InvestSMART

Lumos Diagnostics Holdings Limited (ASX: LDX) - Announcements

Current share price for LDX : $0.110 0.005 (4.35%)+

ASX company news and announcements for Lumos Diagnostics Holdings Limited (LDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Lumos Diagnostics Holdings Limited (LDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Lumos Diagnostics Holdings Limited (LDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Lumos Diagnostics Holdings Limited (LDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$104 Change of Director's Interest Notice - SL 10 Oct 2024 9:11AM $0.043 $0.110 risen by 155.81%
$104 Change of Director's Interest Notice - CR 10 Oct 2024 9:06AM $0.043 $0.110 risen by 155.81%
$104 Change of Director's Interest Notice - BLG 10 Oct 2024 9:03AM $0.043 $0.110 risen by 155.81%
$104 Change in substantial holding from RYD 9 Oct 2024 4:29PM $0.043 $0.110 risen by 155.81%
$104 Lumos and BARDA Partnership - Investor Briefing 9 Oct 2024 3:31PM $0.043 $0.110 risen by 155.81%
$104 Notification regarding unquoted securities - LDX 9 Oct 2024 11:45AM $0.042 $0.110 risen by 161.90%
$104 Application for quotation of securities - LDX 9 Oct 2024 11:39AM $0.042 $0.110 risen by 161.90%
$104 Lumos Successfully Completes Retail Entitlement Offer 8 Oct 2024 8:52AM $0.041 $0.110 risen by 168.29%
$104 Lumos and BARDA Partner to Support FebriDx CLIA Waiver Study 3 Oct 2024 9:33AM $0.037 $0.110 risen by 197.30%
$104 Lumos Awarded National Contract with MediGroup for FebriDx 25 Sep 2024 12:23PM $0.038 $0.110 risen by 189.47%
$104 Ceasing to be a substantial holder 23 Sep 2024 4:18PM $0.034 $0.110 risen by 223.53%
$104 Change in substantial holding from RYD 23 Sep 2024 2:35PM $0.034 $0.110 risen by 223.53%
$104 Investor Roadshow Presentation 23 Sep 2024 9:43AM $0.033 $0.110 risen by 233.33%
$104 Lumos Achieves First Phase 2 Milestone in Hologic Agreement 20 Sep 2024 10:11AM $0.034 $0.110 risen by 223.53%
$104 Change in substantial holding 19 Sep 2024 4:43PM $0.033 $0.110 risen by 233.33%
$104 Change in substantial holder 16 Sep 2024 2:12PM $0.034 $0.110 risen by 223.53%
$104 Change in substantial holding 16 Sep 2024 10:54AM $0.036 $0.110 risen by 209.86%
$104 Lumos Appoints Thermo Fisher Scientific as US Distributor 16 Sep 2024 9:28AM $0.034 $0.110 risen by 223.53%
$104 Change in substantial holding from RYD 13 Sep 2024 3:52PM $0.035 $0.110 risen by 214.29%
$104 Application for quotation of securities - LDX 12 Sep 2024 10:50AM $0.035 $0.110 risen by 214.29%
$104 Letter to Ineligible Shareholders 11 Sep 2024 9:02AM $0.038 $0.110 risen by 193.33%
$104 Letter to Eligible Shareholders 11 Sep 2024 9:02AM $0.038 $0.110 risen by 193.33%
$104 Retail Entitlement Offer Booklet 11 Sep 2024 9:01AM $0.038 $0.110 risen by 193.33%
$104 Retail Entitlement Offer Opens 11 Sep 2024 9:01AM $0.038 $0.110 risen by 193.33%
$104 Lumos Successfully Completes Institutional Entitlement Offer 6 Sep 2024 8:54AM $0.046 $0.110 risen by 139.13%

176 - 200 of 544 results

Page 8 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.